

☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* <u>IPSA (INNOVEN PARTENAIRES S.A.)</u> (Last) (First) (Middle) <u>10 RUE DE LA PAIX</u> (Street) <u>PARIS</u> <u>10</u> <u>75002</u> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>EYEGATE PHARMACEUTICALS INC</u> [<u>EYEG</u>]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <u>X</u> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>02/19/2015</u>	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned										
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	02/19/2015		C		524,998	A	(1)	524,998	I	See Footnote ⁽²⁾⁽³⁾
Common Stock	02/19/2015		C		169,306	A	(4)	694,304	I	See Footnote ⁽²⁾⁽⁵⁾
Common Stock	02/19/2015		C		261,314	A	(6)	955,618	I	See Footnote ⁽²⁾⁽⁷⁾
Common Stock	02/19/2015		C		138,194	A	\$4.2	1,093,812	I	See Footnote ⁽²⁾⁽⁸⁾
Common Stock	02/19/2015		P		366,667	A	\$6	1,460,479	I	See Footnote ⁽²⁾⁽⁹⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series B Preferred Stock	(1)	02/19/2015		C			524,998	(1)	(1)	Common Stock	524,998	\$0	0	I	See Footnote(2)(3)
Series C Preferred Stock	(4)	02/19/2015		C			169,306	(4)	(4)	Common Stock	169,306	\$0	0	I	See Footnote(2)(5)
Series D Preferred Stock	(6)	02/19/2015		C			261,314	(6)	(6)	Common Stock	261,314	\$0	0	I	See Footnote(2)(7)
Convertible Promissory Note	\$4.2	02/19/2015		P		\$580,415		02/19/2015	06/06/2015	Common Stock	138,194	\$580,415	\$580,415	I	See Footnote(2)(10)
Convertible Promissory Note	\$4.2	02/19/2015		C			\$580,415	02/19/2015	06/06/2015	Common Stock	138,194	\$0	0	I	See Footnote(2)(10)

Explanation of Responses:

1. Upon closing of the Issuer's initial public offering, each share of Series B Preferred Stock converted automatically into shares of common stock of the Issuer on a 10.94-for-one basis, and had no expiration date.
2. Innoven Partenaires S.A. ("IPSA") is the manager of each of Innoven 2002 FCPI No.6, Innoven 2003 FCPI No.7, FCPI Innoven Europe, FCPI Innoven Europe 2, FCPI Innoven Europe 3, FCPI Innoven Capital, FCPI Innoven Capital 2, FCPI Poste Innovation, FCPI Poste Innovation 2, FCPI Poste Innovation 3, FCPI Poste Innovation 5, FCPI Poste Innovation 6, FCPI Poste Innovation 9 and FCPI La Banque Postale Innovation 1 (collectively, the "Funds"). Voting and investment power over the shares held by each of the Funds may be deemed to be shared with IPSA. Each of Jean-Michel Paulhac ("Paulhac") and Thomas Balland ("Balland") are directors of IPSA. Each of Paulhac and Balland disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein.
3. Represents 26,994, 71,111, 16,416, 711,099, 428,115, 599,019, 817,685, 2,203,862, 885,941, and 4,288 shares held by Innoven 2002 FCPI No.6, Innoven 2003 FCPI No.7, FCPI Innoven Europe, FCPI Poste Innovation, FCPI Poste Innovation 2, FCPI Poste Innovation 3, FCPI Poste Innovation 5, FCPI Poste Innovation 6, FCPI Poste Innovation 9, and FCPI La Banque Postale Innovation 1, respectively.
4. Upon closing of the Issuer's initial public offering, each share of Series C Preferred Stock converted automatically into shares of common stock of the Issuer on a 9.60-for-one basis, and had no expiration date.
5. Represents 324,574, 31,532, 217,235, 89,946, 139,349, 269,507 and 786,837 shares held by FCPI Innoven Europe, FCPI Innoven Europe 2, FCPI Poste Innovation, FCPI Poste Innovation 2, FCPI Poste Innovation 3, FCPI Poste Innovation 5 and FCPI La Banque Postale Innovation 1, respectively.
6. Upon closing of the Issuer's initial public offering, each share of Series D Preferred Stock converted automatically into shares of common stock of the Issuer on a 10.96-for-one basis, and had no expiration date.
7. Represents 1,163, 527,940, 429,985, 361,720, 84,327, 920,096, 219,702, 219,862, 216 and 104,236 shares held by FCPI Innoven Europe, FCPI Innoven Europe 2, FCPI Innoven Europe 3, FCPI Innoven Capital, FCPI Innoven Capital 2, FCPI Poste Innovation, FCPI Poste Innovation 2, FCPI Poste Innovation 3, and FCPI La Banque Postale Innovation 1, respectively.
8. Represents 5,791, 7,865, 31,161, 50,953, 39,160, 32,943, 7,680, 230,238, 149,680, 193,633, 210,214, 200,716, 80,706 and 81,544 shares held by Innoven 2002 FCPI No.6, Innoven 2003 FCPI No.7, FCPI Innoven Europe, FCPI Innoven Europe 2, FCPI Innoven Europe 3, FCPI Innoven Capital, FCPI Innoven Capital 2, FCPI Poste Innovation, FCPI Poste Innovation 2, FCPI Poste Innovation 3, FCPI Poste Innovation 5, FCPI Poste Innovation 6, FCPI Poste Innovation 9 and FCPI La Banque Postale Innovation 1, respectively.
9. Represents 5,791, 10,006, 36,191, 64,167, 39,160, 32,943, 15,230, 230,238, 149,680, 193,633, 280,566, 231,074, 80,706 and 91,103 shares held by Innoven 2002 FCPI No.6, Innoven 2003 FCPI No.7, FCPI Innoven Europe, FCPI Innoven Europe 2, FCPI Innoven Europe 3, FCPI Innoven Capital, FCPI Innoven Capital 2, FCPI Poste Innovation, FCPI Poste Innovation 2, FCPI Poste Innovation 3, FCPI Poste Innovation 5, FCPI Poste Innovation 6, FCPI Poste Innovation 9 and FCPI La Banque Postale Innovation 1, respectively.
10. Represents 2,141, 5,030, 13,214, 7,550, 70,342, 30,358 and 9,559 shares held by Innoven 2003 FCPI No.7, FCPI Innoven Europe, FCPI Innoven Europe 2, FCPI Innoven Capital 2, FCPI Poste Innovation 5, FCPI Poste Innovation 6 and FCPI La Banque Postale Innovation 1, respectively.

Remarks:

Signed under power of attorney on behalf of Reporting Person

/s/ Authorized Signatory*

02/23/2015

** Signature of Reporting PersonDate

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.